S7748 |
EPZ015666 (GSK3235025)
|
EPZ015666 (GSK3235025) is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs.
|
-
Oncogene, 2024, 10.1038/s41388-024-03049-6
-
Elife, 2024, 12RP89754
-
PLoS Pathog, 2024, 20(9):e1012535
|
|
S8664 |
Pemrametostat (GSK3326595)
|
Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models. |
-
NPJ Precis Oncol, 2024, 8(1):52
-
Elife, 2024, 12RP90683
-
J Med Chem, 2024, 67(8):6064-6080.
|
|
S8111 |
GSK591
|
GSK591 (EPZ015866, GSK3203591) is a potent selective inhibitor of the arginine methyltransferase PRMT5 with IC50 of 11 nM. |
-
J Clin Invest, 2024, e175023
-
Cancer Lett, 2024, 604:217263
-
Heliyon, 2024, 10(19):e37958
|
|
S8112 |
MS023
|
MS023 is a potent, selective, and cell-active Type I PRMT inhibitor with IC50 of 30 nM, 119 nM, 83 nM, 4 nM, and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively.
|
-
J Immunother Cancer, 2024, 12(9)e009603
-
Mol Oncol, 2024, 10.1002/1878-0261.13725
-
Sci Rep, 2024, 14(1):4303
|
|
S7884 |
AMI-1
|
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.
|
-
Cell Death Dis, 2023, 14(4):233
-
Oncogenesis, 2022, 11(1):45
-
Oncogene, 2021, 40(7):1375-1389
|
|
S7832 |
SGC707
|
SGC707 is a potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) with IC50 and Kd of 31 nM and 53 nM, respectively.
|
-
Cell Death Dis, 2022, 13(11):943
-
J Med Chem, 2020, 31
-
Transpl Int, 2020, 33(2):229-243
|
|
S6737 |
C7280948
|
C7280948 is a protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 12.8 μM in vitro. |
-
Cell Death Dis, 2023, 14(4):233
-
Cell Death Dis, 2023, 14(8):512
-
Cell Death Dis, 2023, 14(8):512
|
|
S8624 |
Onametostat (JNJ-64619178)
|
Onametostat (JNJ-64619178) is a PRMT5 inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under different in vitro and cellular conditions, paired with favorable pharmacokinetics and safety properties.
|
-
Sci Rep, 2024, 14(1):4303
-
SLAS Discov, 2024, 29(4):100161
-
Nat Commun, 2023, 14(1):1078
|
|
S8858 |
GSK3368715 3HCl
|
GSK3368715 3HCl is a potent inhibitor of type I protein arginine methyltransferases (PRMT) that inhibits PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81 nM. |
-
Nat Commun, 2023, 14(1):2806
-
Mol Cell, 2023, 83(15):2810-2828.e6
-
JCI Insight, 2022, 7(10)e151353
|
|
S8883 |
LLY-283
|
LLY-283 is a novel and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). LLY-283 inhibits PRMT5 enzymatic activity in vitro and in cells with IC50 of 22 nM and 25 nM, respectively. LLY-283 shows antitumor activity. |
-
Nat Commun, 2023, 14(1):1078
-
J Pharm Anal, 2023, 13(6):590-602
-
Ecotoxicol Environ Saf, 2022, 243:113992
|
|
S7820 |
EPZ020411 2HCl
|
EPZ020411 is a potent and selective small molecule PRMT6 inhibitor with an IC50 of 10 nM. |
-
Theranostics, 2024, 14(10):4090-4106
-
Nat Commun, 2023, 14(1):1430
-
Inflamm Res, 2022, 71(3):309-320
|
|
S8209 |
HLCL-61 HCL
|
HLCL-61 hydrochloride is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia. |
-
Front Immunol, 2019, 10:174
-
Nat Commun, 2018, 9(1):1572
-
Cancer Res, 2018, 78(20):5731-5740
|
|
S8147 |
MS049
|
MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively. |
-
Theranostics, 2024, 14(10):4090-4106
-
Front Cell Dev Biol, 2021, 9:741736
-
Research Square, 2021, 10.21203/rs.3.rs-620216/v1
|
|
S0855 |
TC-E 5003
|
TC-E 5003 (NSC 30176, Compound 2e) is a selective inhibitor of protein arginine methyltransferase 1 (PRMT1) with IC50 of 1.5 μM. TC-E 5003 modulates the lipopolysaccharide (LPS)-induced AP-1 and NF-κB signaling pathways and can possibly be further developed as an anti-inflammatory compound. |
-
Mol Ther, 2023, 10.1016/j.ymthe.2023.09.011
-
Cell Death Dis, 2023, 14(4):233
|
|
S8340 |
SGC2085
|
SGC2085 is a potent and selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) inhibitor with an IC50 value of 50 nM and >100-fold selective over other PRMTs.
|
-
Cell Rep, 2022, 39(12):110994
|
|
S8479 |
LLY-284
|
LLY-284 is the diastereomer of LLY-283, which is a potent and selective SAM-competitive chemical probe for PRMT5. LLY-284 is much less active than LLY-283 and can be used as a negative control for LLY-283. |
|
|
E1600New |
AMG-193
|
AMG-193 is an orally active and MTA-cooperative inhibitor of PRMT5 with potent biochemical and cellular activity. AMG-193, in combination with MTA, selectively targets and inhibits the growth of MTAP-deficient tumor cells by suppressing PRMT5, with an IC50 of 0.107 μM, while sparing normal cells that possess wild-type MTAP. AMG-193 also exhibits antitumor activity. |
|
|
E2887 |
MS023 hydrochloride
|
MS023 hydrochloride(Compound 3) is a potent, selective and cell-active inhibitor of human type I protein arginine methyltransferases (PRMT), with IC50 values of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively. |
|
|
S5445 |
AMI-1 (free acid)
|
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively. |
|
|
E1024 |
MRTX1719
|
MRTX1719 is a potent, selective inhibitor of the protein arginine methyltransferase 5·methylthioadenosine phosphorylase complex (PRMT5•MTA), a potentially tumor-selective target for therapeutic intervention. |
|
|
S0184 |
XY1
|
XY1 is an inactive, close analog of SGC707 that can be used as the negative control for SGC707. SGC707 is a potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) with IC50 and Kd of 31 nM and 53 nM, respectively. |
|
|
E4612New |
iCARM1
|
iCARM1 (CARM1-IN-6) is a potent and selective inhibitor of protein arginine methyltransferase CARM1 (PRMT4) with an IC50 of 12.3 μM. It potently suppresses breast cancer cell growth both in vitro and in vivo and can be used in cancer research. |
|
|
E4701New |
CMP-5
|
CMP5 is a potent and selective small molecule inhibitor of PRMT5. It is found to selectively block S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. It also exhibit potential for research into treatment for EBV+ lymphomas and other B-cell NHL subtypes. |
|
|
E1349New |
TNG908
|
TNG908 is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model. |
|
|
E1658New |
PRT543
|
PRT543 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with broad antitumor activity in vitro and in vivo. It also inhibits the methyltransferase activity of the PRMT5/MEP50 complex with an IC50 of 10.8 nM. |
|
|
E1088 |
TP-064
|
TP-064 is a potent and selective small molecule inhibitor of PRMT4 with IC50 < 10 nM, >100 fold more selective for PRMT4 than other PRMTs. |
-
Cell Rep Med, 2023, 4(12):101326
|
|
S7748 |
EPZ015666 (GSK3235025)
|
EPZ015666 (GSK3235025) is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs.
|
- Oncogene, 2024, 10.1038/s41388-024-03049-6
- Elife, 2024, 12RP89754
- PLoS Pathog, 2024, 20(9):e1012535
|
|
S8664 |
Pemrametostat (GSK3326595)
|
Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models. |
- NPJ Precis Oncol, 2024, 8(1):52
- Elife, 2024, 12RP90683
- J Med Chem, 2024, 67(8):6064-6080.
|
|
S8111 |
GSK591
|
GSK591 (EPZ015866, GSK3203591) is a potent selective inhibitor of the arginine methyltransferase PRMT5 with IC50 of 11 nM. |
- J Clin Invest, 2024, e175023
- Cancer Lett, 2024, 604:217263
- Heliyon, 2024, 10(19):e37958
|
|
S8112 |
MS023
|
MS023 is a potent, selective, and cell-active Type I PRMT inhibitor with IC50 of 30 nM, 119 nM, 83 nM, 4 nM, and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively.
|
- J Immunother Cancer, 2024, 12(9)e009603
- Mol Oncol, 2024, 10.1002/1878-0261.13725
- Sci Rep, 2024, 14(1):4303
|
|
S7884 |
AMI-1
|
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively.
|
- Cell Death Dis, 2023, 14(4):233
- Oncogenesis, 2022, 11(1):45
- Oncogene, 2021, 40(7):1375-1389
|
|
S7832 |
SGC707
|
SGC707 is a potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) with IC50 and Kd of 31 nM and 53 nM, respectively.
|
- Cell Death Dis, 2022, 13(11):943
- J Med Chem, 2020, 31
- Transpl Int, 2020, 33(2):229-243
|
|
S6737 |
C7280948
|
C7280948 is a protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 12.8 μM in vitro. |
- Cell Death Dis, 2023, 14(4):233
- Cell Death Dis, 2023, 14(8):512
- Cell Death Dis, 2023, 14(8):512
|
|
S8624 |
Onametostat (JNJ-64619178)
|
Onametostat (JNJ-64619178) is a PRMT5 inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under different in vitro and cellular conditions, paired with favorable pharmacokinetics and safety properties.
|
- Sci Rep, 2024, 14(1):4303
- SLAS Discov, 2024, 29(4):100161
- Nat Commun, 2023, 14(1):1078
|
|
S8858 |
GSK3368715 3HCl
|
GSK3368715 3HCl is a potent inhibitor of type I protein arginine methyltransferases (PRMT) that inhibits PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81 nM. |
- Nat Commun, 2023, 14(1):2806
- Mol Cell, 2023, 83(15):2810-2828.e6
- JCI Insight, 2022, 7(10)e151353
|
|
S8883 |
LLY-283
|
LLY-283 is a novel and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). LLY-283 inhibits PRMT5 enzymatic activity in vitro and in cells with IC50 of 22 nM and 25 nM, respectively. LLY-283 shows antitumor activity. |
- Nat Commun, 2023, 14(1):1078
- J Pharm Anal, 2023, 13(6):590-602
- Ecotoxicol Environ Saf, 2022, 243:113992
|
|
S7820 |
EPZ020411 2HCl
|
EPZ020411 is a potent and selective small molecule PRMT6 inhibitor with an IC50 of 10 nM. |
- Theranostics, 2024, 14(10):4090-4106
- Nat Commun, 2023, 14(1):1430
- Inflamm Res, 2022, 71(3):309-320
|
|
S8209 |
HLCL-61 HCL
|
HLCL-61 hydrochloride is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia. |
- Front Immunol, 2019, 10:174
- Nat Commun, 2018, 9(1):1572
- Cancer Res, 2018, 78(20):5731-5740
|
|
S8147 |
MS049
|
MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 with IC50s of 34 nM and 43 nM, respectively. |
- Theranostics, 2024, 14(10):4090-4106
- Front Cell Dev Biol, 2021, 9:741736
- Research Square, 2021, 10.21203/rs.3.rs-620216/v1
|
|
S0855 |
TC-E 5003
|
TC-E 5003 (NSC 30176, Compound 2e) is a selective inhibitor of protein arginine methyltransferase 1 (PRMT1) with IC50 of 1.5 μM. TC-E 5003 modulates the lipopolysaccharide (LPS)-induced AP-1 and NF-κB signaling pathways and can possibly be further developed as an anti-inflammatory compound. |
- Mol Ther, 2023, 10.1016/j.ymthe.2023.09.011
- Cell Death Dis, 2023, 14(4):233
|
|
S8340 |
SGC2085
|
SGC2085 is a potent and selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) inhibitor with an IC50 value of 50 nM and >100-fold selective over other PRMTs.
|
- Cell Rep, 2022, 39(12):110994
|
|
E1600New |
AMG-193
|
AMG-193 is an orally active and MTA-cooperative inhibitor of PRMT5 with potent biochemical and cellular activity. AMG-193, in combination with MTA, selectively targets and inhibits the growth of MTAP-deficient tumor cells by suppressing PRMT5, with an IC50 of 0.107 μM, while sparing normal cells that possess wild-type MTAP. AMG-193 also exhibits antitumor activity. |
|
|
E2887 |
MS023 hydrochloride
|
MS023 hydrochloride(Compound 3) is a potent, selective and cell-active inhibitor of human type I protein arginine methyltransferases (PRMT), with IC50 values of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively. |
|
|
S5445 |
AMI-1 (free acid)
|
AMI-1 is a potent and specific Histone Methyltransferase (HMT) inhibitor with IC50 of 3.0 μM and 8.8 μM for yeast Hmt1p and human PRMT1, respectively. |
|
|
E1024 |
MRTX1719
|
MRTX1719 is a potent, selective inhibitor of the protein arginine methyltransferase 5·methylthioadenosine phosphorylase complex (PRMT5•MTA), a potentially tumor-selective target for therapeutic intervention. |
|
|
E4612New |
iCARM1
|
iCARM1 (CARM1-IN-6) is a potent and selective inhibitor of protein arginine methyltransferase CARM1 (PRMT4) with an IC50 of 12.3 μM. It potently suppresses breast cancer cell growth both in vitro and in vivo and can be used in cancer research. |
|
|
E4701New |
CMP-5
|
CMP5 is a potent and selective small molecule inhibitor of PRMT5. It is found to selectively block S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. It also exhibit potential for research into treatment for EBV+ lymphomas and other B-cell NHL subtypes. |
|
|
E1349New |
TNG908
|
TNG908 is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model. |
|
|
E1658New |
PRT543
|
PRT543 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with broad antitumor activity in vitro and in vivo. It also inhibits the methyltransferase activity of the PRMT5/MEP50 complex with an IC50 of 10.8 nM. |
|
|
E1088 |
TP-064
|
TP-064 is a potent and selective small molecule inhibitor of PRMT4 with IC50 < 10 nM, >100 fold more selective for PRMT4 than other PRMTs. |
- Cell Rep Med, 2023, 4(12):101326
|
|